DOCSLIB.ORG

In This Issue Prophylaxis Against Human Papillomavirus Infections with Gardasil® Vaccine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
In This Issue Prophylaxis Against Human Papillomavirus Infections with Gardasil® Vaccine Volume IX, No. VI November/December 2006 Mandy C. Leonard, Pharm.D., BCPS Assistant Director, Drug Information Service Editor Prophylaxis Against Human Papillomavirus Infections with Gardasil® Vaccine Meghan K. Lehmann, Pharm.D., BCPS by Jaime Anderson, Pharm.D. Drug Information Specialist Editor Introduction Dana L. Travis, R.Ph. T he recent development of two vac- HPV. Worldwide, the incidence of Drug Information Pharmacist cines targeting the prevention of hu- cervical cancer is estimated to be 10% Editor man papillomavirus (HPV) infection of cancers in women and is the second has created both anticipation and con- most common cause of death from David A. White, B.S., R.Ph. Restricted Drug Pharmacist troversy in the public and medical cancer in women after breast cancer. Associate Editor communities. Gardasil® (Merck and Approximately 80% of cervical can- Marcia J. Wyman, Pharm.D. Co., Inc.), approved by the Food and cers occur in less-developed coun- Drug Administration (FDA) on June 8, tries, where access to screening and Drug Information Pharmacist Associate Editor 2006, is a quadrivalent vaccine consist- treatment for HPV and cervical cancer 3 ing of recombinant HPV Types 6, 11, are limited. Amy T. Sekel, Pharm.D. 16, and 18.1 A second bivalent vaccine D rug Information Pharmacist Associate Editor containing recombinant HPV types 16 There are more than 100 types of In this Issue ® and 18, Cervarix (GlaxoSmithKline), HPV that have been identified, of 2 David Kvancz, M.S., R.Ph., FASHP is currently under investigation. which approximately 18 have been Chief Pharmacy Officer determined to be oncogenic.4 Of the Morton Goldman, Pharm.D., BCPS In the United States, the estimated oncogenic HPV types, HPV16 and Director, Pharmacotherapy Services prevalence of HPV infection is 20 to HPV18 account for about 50% and 40% in sexually active 20-year-old 20% of cervical cancers, respec- 3 In This Issue: women; the estimated lifetime risk for tively. It is believed that microtrauma • Gardasil® o ne or more genital HPV infections for or erosion of the overlying epithelial 3 • Medication Safety: Promethazine a ll women is at least 75%. Approxi- layers is a contributing factor allow- m ately 70% of these infections are ing viral particles to establish infec- c leared within 1 year, while 91% are tion in the basal epithelial cells.3 The c leared within 2 years. It is not well histologic precursor to squamous cell Drug Information Service understood or known whether this sug- cervical cancer is cervical intraepithe- (216) 444-6456, option #1 g ests the amount of viral matter present lial neoplasia (CIN), which has levels h as dropped below detectable levels or of progression from Stage 1 (low- Comprehensive information about i f the virus is completely eliminated.4 grade dysplasia) to Stage 2/3 medications, biologics, nutrients, (moderate to high-grade dysplasia). and drug therapy Human papillomaviruses infect the The histologic precursor for cervical stratified squamous epithelia of skin adenocarcinoma is adenocarcinoma in Formulary Information and mucous membranes, where they situ (AIS).5 The disease course from form benign lesions that have the po- HPV infection to development of Medication Inservices tential of progressing to invasive can- malignancy usually takes at least cers. Virtually all cases of cervical can- 10 years, with the risk of cervical can- cer result from sexual transmission of cer being highest in women over 40 years of age.3 A likely result of physiological proximity, Protocol 005, a double-blind, randomized, placebo-controlled, HPV also causes an estimated 35 to 50% of vulvar and vaginal multi-center Phase II trial conducted in women 16 to 23 years cancers. Additionally, HPV is the cause of genital warts old evaluated a vaccine for HPV type 16. Participants received (condyloma acuminata) which can be located in the cervico- 40 mcg (0.5 mL) intramuscular doses of the vaccine (n=768) vaginal, vulvar, and external genitalia areas but rarely pro- or placebo (n=765) at day 0, month 2, and month 6. Included gresses to cancer.5 The inclusion of recombinant HPV6 and were non-pregnant women who had no prior abnormal Papani- HPV11 in Gardasil® is targeted to protect against genital colaou (Pap) smears and had <5 male sex partners. Follow-up warts, as these two types of HPV account for approximately occurred at months 7 and 12, and every 6 months thereafter 90% of cases.6 until month 48. The primary outcome was persistent HPV type 16 infection, defined as having a cervical biopsy positive for Pharmacology CIN or cervical cancer with DNA probes yielding HPV type Gardasil® consists of highly purified virus-like particles 16, or being negative for HPV type 16 on day 0 and month 7 (VLPs) of the major capsid (L1) protein of HPV types 6, 11, with subsequent HPV type 16 DNA detected at two or more 16, and 18. The L1 proteins are produced by separate fermen- consecutive visits 4 or more months apart, or HPV type 16 tations in recombinant Saccaromyces cerevisiae and then self- DNA detected only in a sample collected at the last visit prior assembled into VLPs. These VLPs are released from the to being lost to follow-up. Any adverse events occurring S. cerevisiae cells by cell disruption and are further purified. within 14 days of being vaccinated or body temperatures The vaccine is then finalized by adsorbing the VLPs to an alu- >37.7C (100F) within 5 days of being vaccinated were also minum-containing adjuvant (amorphous aluminum hydroxy- analyzed. Median follow-up was 17.4 months. Forty-one cases phosphate sulfate).5,6 of HPV type 16 infections occurred in the placebo group of which 31 were persistent HPV type 16 infections without CIN, Clinical Studies of Gardasil® 9 were HPV type 16-related CIN (5=grade 1, 4=grade 2), and The approval of Gardasil® was guided largely by the over- 1 was an HPV type 16 positive patient lost to follow-up. In whelming evidence for efficacy determined in four separate the placebo group, the incidence of persistent HPV type 16 Phase II and III trials.1 The Phase II trials were termed Proto- infections was 3.8 per 100 woman-years at risk, whereas the col 005, which only evaluated a vaccine for HPV type 16, and incidence in the vaccine group was 0 per 100 woman-years at Protocol 007, which evaluated the quadrivalent vaccine for risk (95% CI 90-100; P<0.001). There were no significant HPV types 6, 11, 16, and 18.5,7,8 The FUTURE I (Females differences between the groups for adversities with injection United to Unilaterally Reduce Ecto/Endocervical Disease) and site pain being the most frequently reported adverse event. FUTURE II trials were Phase III studies which also evaluated The authors concluded that administration of a monovalent the quadrivalent vaccine.6,9 In all four trials, the primary HPV type 16 vaccine reduced the incidence of HPV type 16 analyses of efficacy were conducted in the per-protocol effi- infections and related CIN; however, a larger study was war- cacy (PPE) population, which consisted of those individuals ranted to determine if the vaccine prevents clinical disease. who had received the complete series of three vaccinations Also, a multivalent vaccine including other types of HPV within 1 year of study enrollment, did not deviate from the would be more beneficial.7 study protocol, and who were polymerase-chain reaction (PCR) negative for the relevant HPV types prior to the first Protocol 007, a double-blind, randomized, placebo-controlled, dose and through 1 month following the third dose.5 multi-center Phase II trial conducted in women 16 to 23 years Table 1: Combined Analyses of Efficacy of Gardasil® in the Per-Protocol Efficacy Population5 ® Population Gardasil Placebo % Efficacy Number of Number of (95% Confidence N N Cases Cases Interval) HPV type 16- or HPV18-Related CIN Stage 2/3 or AIS Combined Protocols 8487 0 8460 53 100 (92.89-100) HPV type 6-, 11-, 16-, or 18-Related CIN (stages 1, 2/3) or AIS Combined Protocols 7858 4 7861 83 95.2 (87.2-98.7) HPV type 6-, 11-, 16-, or 18-Related Genital Warts Combined Protocols 7897 1 7899 91 98.9 (93.7-100) CIN = Cervical Intraepithelial Neoplasia AIS = Adenocarcinoma in situ old evaluated the efficacy and safety of a quadrivalent cervical cancer, genital warts, VIN, VaIN, or vulvar/vaginal can- HPV vaccine against HPV types 6, 11, 16, and 18. Inclu- cer. The study was conducted in women 16 to 23 years old. The sion criteria were the same as in Protocol 005, except par- vaccine or placebo was administered at day 1, month 2, and ticipants were required to have had <4 male sex partners. month 6. Follow-up occurred at months 3 and 7, and then every After receiving 0.5 mL doses of vaccine (type 6=20 mcg, 6 months (total follow-up period not specified). After an average type 11=40 mcg, type 16=40 mcg, and type 18=20 mcg; of 17 months of follow-up the vaccine prevented 100% of HPV n=276) or placebo (n=275) at day 1, month 2, and month 6-, 11-, 16-, and 18-related CIN grades 1-3, genital warts, and 6, patients were followed-up at months 7 and 12, and then VIN/VaIN of any grade (95% CI 88-100). No cases of the com- every 6 months thereafter until month 36. Primary out- posite endpoint occurred in the vaccine group compared to come was the composite of persistent infection associated 40 cases in the placebo group.
Load more

Recommended publications
  • Adult Vaccines
    What do flu, whooping cough, measles, shingles and pneumonia have in common? 1 They’re viruses that can make you very sick. 2 Vaccines can help prevent them. Protect yourself and those you care about. Get vaccinated at a network pharmacy near you. • Ask your pharmacist which vaccines are right for you. • Find out if your pharmacist can administer the recommended vaccinations. • Many vaccinations are covered by your plan at participating retail pharmacies. • Don’t forget to present your member ID card to the pharmacist at the time of service! The following vaccines are available and can be administered by pharmacists at participating network pharmacies: • Flu (seasonal influenza) • Meningitis • Travel Vaccines (typhoid, yellow • Tetanus/Diphtheria/Pertussis • Pneumonia fever, etc.) • Hepatitis • Rabies • Childhood Vaccines (MMR, etc.) • Human Papillomavirus (HPV) • Shingles/Zoster See other side for recommended adult vaccinations. The vaccinations you need ALL adults should get vaccinated for1: • Flu, every year. It’s especially important for pregnant women, older adults and people with chronic health conditions. • Tetanus, diphtheria and pertussis (whooping cough). Adults should get a one-time dose of the Tdap vaccine. It’s different from the tetanus vaccine (Td), which is given every 10 years. You may need additional vaccinations depending on your age1: Young adults not yet vaccinated need: Human papillomavirus (HPV) vaccine series (3 doses) if you are: • Female age 26 or younger • Male age 21 or younger • Male age 26 or younger who has sex with men, who is immunocompromised or who has HIV Adults born in the U.S. in 1957 or after need: Measles, mumps, rubella (MMR) vaccine2 Adults should get at least one dose of MMR vaccine, unless they’ve already gotten this vaccine or have immunity to measles, mumps and rubella Adults born in the U.S.
    [Show full text]
  • Viability of B. Typhosus in Stored Shell Oysters
    PUBLIC HEALTH REPORTS VOL. 40 APRIL 24, 1925 No. 17 VIABILITY OF B. TYPHOSUS IN STORED SHELL OYSTERS By CONRAD KINYOuN, Assistant Bacteriologist, hlygienic Laboratory, United Stztes Ptiblic Ilealti Serviee The object of this work was to determine whether oysters con- taminated with B. typhosuis and then stored unider uisual market conditions woul(l remain potentially infectious over a length of time sufficient to allow them to reach the consumer. Conflicting opinions are now current as to the length of time the causative agent of typhoid fever can remain viable in the oyster, and even as to whether the oyster can harbor the organisms at all. Obviouisly an oyster which harbors typhoidl organismns for as short a time as 24 hours becomes a potential infecting, agent for thlat time. Practi- cally it is of interest to know whether the time elapsing between the remov-al of the oyster from the bed and( actual consumption after passing through customary commercial channels is sufficient for oysters to rid themselves of possible infection. As early as 1603, oysters were incriminate(d in intestinal disor(lers, when suspicion was directed toward them by an illness of Henry IV of France (7). It was not uIntil the close of the nineteenth century, however, that oysters and shellfislh as agents of (lisease transmission receive(d particular attention. In October, 1894, Conn focused attention on the oyster by his investigation of the now famous Wesleyan outbreak, an(d thoughl only thlree outbreaks of typhoid fever were definitely traced to the oyster before 19,25, these stimulated wide interest and consequent study, with atten(lant epidemiological and bacteriological investigations.
    [Show full text]
  • Measles: Chapter 7.1 Chapter 7: Measles Paul A
    VPD Surveillance Manual 7 Measles: Chapter 7.1 Chapter 7: Measles Paul A. Gastanaduy, MD, MPH; Susan B. Redd; Nakia S. Clemmons, MPH; Adria D. Lee, MSPH; Carole J. Hickman, PhD; Paul A. Rota, PhD; Manisha Patel, MD, MS I. Disease Description Measles is an acute viral illness caused by a virus in the family paramyxovirus, genus Morbillivirus. Measles is characterized by a prodrome of fever (as high as 105°F) and malaise, cough, coryza, and conjunctivitis, followed by a maculopapular rash.1 The rash spreads from head to trunk to lower extremities. Measles is usually a mild or moderately severe illness. However, measles can result in complications such as pneumonia, encephalitis, and death. Approximately one case of encephalitis2 and two to three deaths may occur for every 1,000 reported measles cases.3 One rare long-term sequelae of measles virus infection is subacute sclerosing panencephalitis (SSPE), a fatal disease of the central nervous system that generally develops 7–10 years after infection. Among persons who contracted measles during the resurgence in the United States (U.S.) in 1989–1991, the risk of SSPE was estimated to be 7–11 cases/100,000 cases of measles.4 The risk of developing SSPE may be higher when measles occurs prior to the second year of life.4 The average incubation period for measles is 11–12 days,5 and the average interval between exposure and rash onset is 14 days, with a range of 7–21 days.1, 6 Persons with measles are usually considered infectious from four days before until four days after onset of rash with the rash onset being considered as day zero.
    [Show full text]
  • Measles Diagnostic Tool
    Measles Prodrome and Clinical evolution E Fever (mild to moderate) E Cough E Coryza E Conjunctivitis E Fever spikes as high as 105ºF Koplik’s spots Koplik’s Spots E E Viral enanthem of measles Rash E Erythematous, maculopapular rash which begins on typically starting 1-2 days before the face (often at hairline and behind ears) then spreads to neck/ the rash. Appearance is similar to “grains of salt on a wet background” upper trunk and then to lower trunk and extremities. Evolution and may become less visible as the of rash 1-3 days. Palms and soles rarely involved. maculopapular rash develops. Rash INCUBATION PERIOD Fever, STARTS on face (hairline & cough/coryza/conjunctivitis behind ears), spreads to trunk, Average 8-12 days from exposure to onset (sensitivity to light) and then to thighs/ feet of prodrome symptoms 0 (average interval between exposure to onset rash 14 day [range 7-21 days]) -4 -3 -2 -1 1234 NOT INFECTIOUS higher fever (103°-104°) during this period rash fades in same sequence it appears INFECTIOUS 4 days before rash and 4 days after rash Not Measles Rubella Varicella cervical lymphadenopathy. Highly variable but (Aka German Measles) (Aka Chickenpox) Rash E often maculopapular with Clinical manifestations E Clinical manifestations E Generally mild illness with low- Mild prodrome of fever and malaise multiforme-like lesions and grade fever, malaise, and lymph- may occur one to two days before may resemble scarlet fever. adenopathy (commonly post- rash. Possible low-grade fever. Rash often associated with painful edema hands and feet. auricular and sub-occipital).
    [Show full text]
  • Kaposi Sarcoma-Associated Herpesvirus Uals Were 2 to 16 Times More Likely to Develop Kaposi Sarcoma Than Were Uninfected Individuals
    Report on Carcinogens, Fourteenth Edition For Table of Contents, see home page: http://ntp.niehs.nih.gov/go/roc Kaposi Sarcoma-Associated Herpesvirus uals were 2 to 16 times more likely to develop Kaposi sarcoma than were uninfected individuals. In some studies, the risk of Kaposi sar- CAS No.: none assigned coma increased with increasing viral load of KSHV (Sitas et al. 1999, Known to be a human carcinogen Newton et al. 2003a,b, 2006, Albrecht et al. 2004). Most KSHV-infected patients who develop Kaposi sarcoma have Also known as KSHV or human herpesvirus 8 (HHV-8) immune systems compromised either by HIV-1 infection or as a re- Carcinogenicity sult of drug treatments after organ or tissue transplants. The timing of infection with HIV-1 may also play a role in development of Ka- Kaposi sarcoma-associated herpesvirus (KSHV) is known to be a posi sarcoma. Acquiring HIV-1 infection prior to KSHV infection human carcinogen based on sufficient evidence from studies in hu- may increase the risk of epidemic Kaposi sarcoma by 50% to 100%, mans. This conclusion is based on evidence from epidemiological compared with acquiring HIV-1 infection at the same time as or after and molecular studies, which show that KSHV causes Kaposi sar- KSHV infection. Nevertheless, patients with the classic or endemic coma, primary effusion lymphoma, and a plasmablastic variant of forms of Kaposi sarcoma are not suspected of having suppressed im- multicentric Castleman disease, and on supporting mechanistic data. mune systems, suggesting that immunosuppression is not required KSHV causes cancer, primarily but not exclusively in people with for development of Kaposi sarcoma.
    [Show full text]
  • Varicella (Chickenpox): Questions and Answers Q&A Information About the Disease and Vaccines
    Varicella (Chickenpox): Questions and Answers Q&A information about the disease and vaccines What causes chickenpox? more common in infants, adults, and people with Chickenpox is caused by a virus, the varicella-zoster weakened immune systems. virus. How do I know if my child has chickenpox? How does chickenpox spread? Usually chickenpox can be diagnosed by disease his- Chickenpox spreads from person to person by direct tory and appearance alone. Adults who need to contact or through the air by coughing or sneezing. know if they’ve had chickenpox in the past can have It is highly contagious. It can also be spread through this determined by a laboratory test. Chickenpox is direct contact with the fluid from a blister of a per- much less common now than it was before a vaccine son infected with chickenpox, or from direct contact became available, so parents, doctors, and nurses with a sore from a person with shingles. are less familiar with it. It may be necessary to perform laboratory testing for children to confirm chickenpox. How long does it take to show signs of chickenpox after being exposed? How long is a person with chickenpox contagious? It takes from 10 to 21 days to develop symptoms after Patients with chickenpox are contagious for 1–2 days being exposed to a person infected with chickenpox. before the rash appears and continue to be conta- The usual time period is 14–16 days. gious through the first 4–5 days or until all the blisters are crusted over. What are the symptoms of chickenpox? Is there a treatment for chickenpox? The most common symptoms of chickenpox are rash, fever, coughing, fussiness, headache, and loss of appe- Most cases of chickenpox in otherwise healthy children tite.
    [Show full text]
  • Vaccine Information Statement
    VACCINE INFORMATION STATEMENT Many Vaccine Information Statements are available in Spanish and other languages. MMRV (Measles, Mumps, Rubella, and See www.immunize.org/vis Hojas de información sobre vacunas están Varicella) Vaccine: What You Need to Know disponibles en español y en muchos otros idiomas. Visite www.immunize.org/vis 1 Why get vaccinated? 2 MMRV Vaccine Measles, mumps, rubella, and varicella are viral diseases that can MMRV vaccine may be given to children 12 months through 12 have serious consequences. Before vaccines, these diseases were years of age. Two doses are usually recommended: very common in the United States, especially among children. First dose: 12 through 15 months of age They are still common in many parts of the world. Second dose: 4 through 6 years of age Measles A third dose of MMR might be recommended in certain mumps Measles virus causes symptoms that can include fever, cough, outbreak situations. runny nose, and red, watery eyes, commonly followed by a rash There are no known risks to getting MMRV vaccine at the same that covers the whole body. time as other vaccines. Measles can lead to ear infections, diarrhea, and infection of the lungs (pneumonia). Rarely, measles can cause brain damage or Instead of MMRV, some children 12 months death. through 12 years of age might get 2 separate Mumps shots: MMR (measles, mumps and rubella) and Mumps virus causes fever, headache, muscle aches, tiredness, chickenpox (varicella). MMRV is not licensed for loss of appetite, and swollen and tender salivary glands under the people 13 years of age or older.
    [Show full text]
  • WHO African Regional Measles and Rubella Surveillance Guidelines
    AFRICAN REGIONAL GUIDELINES FOR MEASLES AND RUBELLA SURVEILLANCE WHO Regional Office for Africa Revised April 2015 African Regional guidelines for measles and rubella surveillance- Draft version April 2015. 1 Contents ACRONYMS ............................................................................................................................................. 4 I. INTRODUCTION ............................................................................................................................... 5 II. MEASLES DISEASE ........................................................................................................................... 5 i. Epidemiology of measles ............................................................................................................ 5 ii. Clinical features of measles ........................................................................................................ 6 iii. Complications of Measles ........................................................................................................... 7 iv. Measles Immunity ....................................................................................................................... 8 III. RUBELLA DISEASE ........................................................................................................................ 9 i. Epidemiology and clinical features: ............................................................................................ 9 ii. Congenital Rubella Syndrome ....................................................................................................
    [Show full text]
  • Kaposi's Sarcoma and Psoriasis in a Naïve HIV-Positive Patient
    INFECT DIS TROP MED 2019; 5: E569 Kaposi’s Sarcoma and Psoriasis in a naïve HIV-positive patient: a case report F. D’Andrea1, A. Facciolà1, M. G. Coco1, C. Micali1, I. Paolucci2, D. Maranto2, M. R. Lo Presti Costantino2, D. Larnè1, P. Mondello2, G. F. Pellicanò3 1Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy 2Unit of Infectious Diseases, “G. Martino” University Hospital, Messina, Italy 3Department of Human Pathology of the Adult and the Developmental Age “G. Barresi”, University of Messina, Messina, Italy ABSTRACT: The introduction of combined Anti-Retroviral Therapy has modified the natural history of Hu- man Immunodeficiency Virus (HIV) infection, leading to an increase in life expectancy of the patients living with HIV. Immune deficiency can lead to opportunistic infections and an increased risk of autoimmune dis- ease and malignancy. Here we describe the case of a patient affected by psoriasis, HIV infection and Kapo- si’s Sarcoma. — Keywords: Kaposi’s Sarcoma, Human Immunodeficiency Virus, Psoriasis. INTRODUCTION CASE REPORT The introduction of combined Anti-Retroviral Therapy A 37-year-old man, from Sri-Lanka, was accompanied (cART) has modified the natural history of Human Immu- to the clinic of Infectious Diseases of the “G. Marti- nodeficiency Virus (HIV) infection, leading to an increase no” University Hospital in Messina (Messina, Italy) in life expectancy of the patients living with HIV (PLWH)1- because of a Kaposi’s Sarcoma in nodular phase con- 21. However, it is not able to eliminate the virus22-24. firmed by biopsy. He referred to the dermatologic clin- cART has brought an increased survival and a re- ic for a psoriasis vulgaris poorly responsive to cyclo- duced mortality for Acquired Immune Deficiency Syn- phosphamide.
    [Show full text]
  • Incubation Period of Measles from Exposure to Prodrome ■ Exposure to Rash Onset Averages 11 to 12 Days
    Measles Paul Gastanaduy, MD; Penina Haber, MPH; Paul A. Rota, PhD; and Manisha Patel, MD, MS Measles is an acute, viral, infectious disease. References to measles can be found from as early as the 7th century. The Measles disease was described by the Persian physician Rhazes in the ● Acute viral infectious disease 10th century as “more to be dreaded than smallpox.” ● First described in 7th century In 1846, Peter Panum described the incubation period of ● Vaccines first licensed include measles and lifelong immunity after recovery from the disease. measles in 1963, MMR in 1971, John Enders and Thomas Chalmers Peebles isolated the virus in and MMRV in 2005 human and monkey kidney tissue culture in 1954. The first live, ● Infection nearly universal attenuated vaccine (Edmonston B strain) was licensed for use in during childhood in the United States in 1963. In 1971, a combined measles, mumps, prevaccine era and rubella (MMR) vaccine was licensed for use in the United ● Still common and often fatal States. In 2005, a combination measles, mumps, rubella, and in developing countries varicella (MMRV) vaccine was licensed. Before a vaccine was available, infection with measles virus was nearly universal during childhood, and more than 90% of persons were immune due to past infection by age 15 years. Measles is still a common and often fatal disease in developing countries. The World Health Organization estimates there were 142,300 deaths from measles globally in 2018. In the United 13 States, there have been recent outbreaks; the largest occurring in 2019 primarily among people who were not vaccinated.
    [Show full text]
  • Measles, Mumps, Rubella, Varicella Jul 2020
    Measles, Mumps, Rubella, Varicella Jul 2020 Health Care Professional Programs Measles, mumps, rubella and varicella are vaccine-preventable diseases. The efficacy of two doses of vaccine (one for rubella) is close to 100% for measles, 76-95% for mumps, 95% for rubella, and 98-100% for varicella. If born before 1970, you may be immune to measles, mumps and rubella due to naturally acquired infection; after 1970 you most likely received one or two vaccines. You may be immune to varicella due to naturally acquired infection or you may have received one or two vaccines (vaccine introduced in Canada in 1999). If you are unable to locate your vaccination records, revaccination is safe unless you are pregnant or immunocompromised. Measles: Measles is one of the most highly communicable infectious diseases with greater than 90% secondary attack rates among susceptible persons. Symptoms include fever, cough, runny nose, red eyes, Koplik spots (white spots on the inner lining of the mouth), followed by a rash that begins on the face, advances to the trunk and then to the arms and legs. The virus is transmitted by the airborne route, respiratory droplets, or direct contact with nasal or throat secretions of infected persons. The incubation period is 7 to 18 days. Cases are infectious from 4 days before the beginning of the prodromal period to 4 days after rash onset. Mumps: Mumps virus is highly contagious and is transmitted primarily by droplet spread, as well as by direct contact with saliva of an infected person. Symptoms of mumps virus infection include fever, headache and muscle aches followed by swelling in one or more salivary glands (usually parotid gland).
    [Show full text]
  • Measles, Mumps, Rubella, and Varicella (MMRV)
    Vaccine Information Sheet April 2017 | www.hss.gov.nt.ca Measles, Mumps, Rubella, and Varicella (MMRV) The best way to protect your child against measles, mumps, rubella, and varicella is to What is MMRV Vaccine? get a MMRV vaccine. All children between the The MMRV vaccine is a safe and effective way to keep ages of 12 months to 12 years should get this your child from getting very sick from the real disease. It vaccine. This can also be given separately as is approved by Health Canada. The MMRV vaccine (shot) MMR and Var vaccines. is made with a tiny amount of weakened germs that do not cause disease. Vaccines help the immune system learn how to protect itself against real diseases. Are these diseases serious? cause an itchy rash that looks like small water blisters. Measles (rubeola), also known as “red measles”, is a Varicella can be serious and even life threatening, virus that causes blotchy red rash, fever, cough, runny especially for newborn babies and adults who have nose, and red, watery eyes. In some cases measles can weakened immune systems. cause swelling of the brain leading to seizures, hearing loss, or even death. • Complications from varicella infection include: • Pneumonia (lung infection), Mumps is a virus that causes painful swelling of the • Encephalitis (swelling of the brain), cheeks and neck, fever, dry mouth, headache, earache, • Bacterial infections of the skin. fatigue, sore muscles, loss of appetite, and trouble talking, chewing, or swallowing. Mumps can also cause Once you have the varicella virus it will stay with you deafness, meningitis, and infections of the testicles or forever.
    [Show full text]